What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday ...
DRUG.US股价暴涨52倍背后的秘密：Bright Minds Biosciences是如何颠覆市场的？
在近期的美股市场上，Bright Minds Biosciences（DRUG.US）以惊人的速度引起了投资者的关注。仅在五个交易日内，该公司的股价飙升了52倍，达到了历史新高。这一异动不仅令市场惊愕，也引发了各界对其背后原因的强烈探讨。那么，是什么驱动了这一股价的疯狂上涨？在这篇文章中，我们将深入分析Bright Minds Biosciences的近期动态、融资计划及其可能对市场带来的长期影响 ...
拟进行1.75亿美元非经纪人定向增发 Bright Minds Biosciences 5个交易日暴涨 ...
周五，Bright Minds Biosciences (DRUG.US)开盘再度大幅拉升，5个交易日暴涨52倍，创历史新高，截至发稿，涨超165%，报57.72美元。消息面上，公司今日宣布，将以每股21.70美元的价格 ("股票发行")进行非经纪人的普通股私募融资。除了股票发行下发行的股票外，公司保留了以每个预先资助的公司权证 (PFWs)以21.699美元每个PFW ...
Bright Minds, Firefly Neuroscience Shares Rise on Collaboration for Clinical Trial Analysis
Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...
greenmarketreport4 天
Bright Minds’ stock explodes after $35M placement, pain drug news
It mirrors a similar move in August 2022, when the firm denied knowledge of material changes before quickly announcing a ...
Bright Minds rally ends as psychedelic stocks extend volatility
After a nearly 15-fold rise in value in the previous session, shares of Bright Minds Biosciences (NASDAQ:DRUG) fell ~29% on ...
科莫兰特资产管理公司增持Bright Minds Biosciences Inc.股份
波士顿——作为Bright Minds Biosciences Inc. (NASDAQ:DRUG)的重要股东，科莫兰特资产管理有限合伙公司(Cormorant Asset Management, LP)通过大规模收购普通股增加了其在该公司的持股。根据最近的SEC文件显示，科莫兰特及其附属公司在截至10月16日的两天内购买了总价值约320万美元的股份。 这些交易涉及多批普通股的购买，每股价格从4.
Firefly和Bright Minds合作开发脑健康人工智能
多伦多 - 专门从事神经系统和精神疾病人工智能(AI)解决方案的Firefly Neuroscience, Inc. (NASDAQ:AIFF)宣布与Bright Minds Biosciences Inc. (CSE:DRUG) ...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR ...
Bright Minds Biosciences Shares Surge 70% on $35M Private Placement
Shares of Bright Minds Biosciences on Friday shot higher after pricing a $35 million private placement. The stock was up 70% at $36.86 in pre-market trading. The company said it has priced the private ...
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist ...
BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain ...
Nasdaq7 天
Bright Minds is Unaware of Any Material Changes
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists ...